Abstract Progress in rectal cancer therapy has been hindered by the lack of effective disease-specific preclinical models that account for the unique molecular profile and biology of rectal cancer. Thus, we developed complementary patient-derived xenograft (PDX) and subsequent in vitro tumor organoid (PDTO) platforms established from pre-neoadjuvant therapy rectal […]
View Original Source at Modeling rectal cancer to advance neoadjuvant precision therapy.